6/3/2010

The FDA ordered GlaxoSmithKline to change the warning label of asthma drugs Serevent and Advair. The long-acting beta-agonists have been shown to worsen asthma symptoms and result in hospitalization or death when used as a stand-alone treatment, according to the agency.

Related Summaries